Paris, France, September 15, 2020 – Determine, a Corcentric company, a leading global provider of SaaS Source-to-Pay and Contract Lifecycle Management solutions announced today that global pharmaceutical group Servier, a Determine customer for more than 13 years,  will migrate to the Determine Cloud Platform to boost the group digital transformation.

Servier has been using the Determine Procurement Solution since 2007 to manage the group’s indirect spend. In 2019, Servier Procurement Team managed more than 50,000 purchase orders in the Determine Solution originated from 2,400 users for a volume of transactions of approximately 1 Billion Euros. Servier made the strategic choice to accelerate its digital transformation in 2020 by opting for a full Saas cloud solution.

Moving to the Cloud empowers Servier to leverage advantages of cloud hosting compared to the former on-premises:

  • More scalability and more flexibility to adapt to the ever changing business and organisational changes
  • Data on the cloud can be accessed remotely through any device
  • Increased collaboration across functions and organisations
  • Access to innovation and continuous  solution updates
  • Control of infrastructure & IT costs
  • Stronger data security

Migrating to the Determine Cloud Platform is in line with the Group’s digital strategy. Since moving to the cloud, our users can access the Determine Procurement solution remotely through any device, it also facilitates data exchange between the solution and the suppliers’ punch-out catalogues and other API applications.  The new version is more user-friendly, our employees like it.”

— Sylvain Feraud, Director of Procurement at Servier

The Servier group is committed to build lasting relationships with its suppliers. This strategy is reflected today in the Group’s decision to renew its trust in Determine and our spend management solutions after 13 years of partnership.”

— Gérard Dahan, SVP EMEA, Determine, a Corcentric company

# # # #

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 150 countries and a total revenue of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group invests on average 25% of its total revenue (excluding generics) every year in research and development and uses all its profits for its development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory, and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.


Eléonore Roucaute
[email protected]